Prostate cancer, particularly metastatic castration-resistant prostate cancer, remains a major clinical challenge due to its complex genetic landscape and resistance to conventional therapies. This poster explores the potential of CRISPR/Cas9 technology to revolutionize the understanding and treatment of prostate cancer. By enabling precise gene editing and genetic barcoding, CRISPR allows for the identification and targeting of metastasis-driving mutations. Also highlights how this approach could offer new avenues for tracking aggressive clones and developing personalized therapies to halt disease progression.
Fill the form below to download the Scientific posters & presentations